Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.78 |
| ▸ | SCN10A | Q9Y5Y9 | 9/20 | 0.73 |
| ▸ | SCN2A | Q99250 | 7/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714112 | 0.87 | ABL1 (1.00) | ABL1SCN10ASCN2ANPC1RAB9A | |
| SCHEMBL31301529 | 0.85 | SCN10A (0.63) | ABL1SCN10ASCN2AMEN1KMT2A | |
| SCHEMBL15390862 | 0.83 | ABL1 (0.69) | ABL1SCN10ASCN2ANPC1RAB9A | |
| SCHEMBL31301428 | 0.81 | SCN10A (0.63) | ABL1SCN10ASCN2AMEN1KMT2A | |
| SCHEMBL24994330 | 0.79 | SCN10A (0.66) | ABL1SCN10ASCN2ANPC1RAB9A | |
| SCHEMBL31301261 | 0.79 | SCN10A (0.55) | ABL1SCN10ASCN2AMEN1KMT2A | |
| SCHEMBL31301547 | 0.79 | SCN10A (0.62) | ABL1SCN10ASCN2ANPC1RAB9A | |
| SCHEMBL27996626 | 0.78 | SCN10A (0.61) | ABL1SCN10ASCN2A | |
| SCHEMBL31301422 | 0.77 | SCN10A (0.52) | ABL1SCN10ASCN2A | |
| SCHEMBL31301271 | 0.77 | SCN10A (0.52) | ABL1SCN10ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | ABL1 524/4885SCN10A 3171/4885SCN2A 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.